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Abstract
Background: Sprouting angiogenesis requires vascular endothelial proliferation, migration and morphogenesis. The
process is regulated by soluble factors, principally vascular endothelial growth factor (VEGF), and via bidirectional
signaling through the Jagged/Notch system, leading to assignment of tip cell and stalk cell identity. The cytokine
transforming growth factor beta (TGF-β) can either stimulate or inhibit angiogenesis via its differential surface
receptor signaling. Here we evaluate changes in expression of angiogenic signaling receptors when bovine aortic
endothelial cells were exposed to TGF-β1 under low serum conditions.
Results: TGF-β1 induced a dose dependent inhibition of tip cell assignment and subsequent angiogenesis on
Matrigel, maximal at 5.0 ng/ml. This occurred via ALK5-dependent pathways and was accompanied by significant
upregulation of the TGF-β co-receptor endoglin, and SMAD2 phosphorylation, but no alteration in Smad1/5
activation. TGF-β1 also induced ALK5-dependent downregulation of Notch1 but not of its ligand delta-like ligand
4. Cell associated VEGFR2 (but not VEGFR1) was significantly downregulated and accompanied by reciprocal
upregulation of VEGFR2 in conditioned medium. Quantitative polymerase chain reaction analysis revealed that this
soluble VEGFR2 was not generated by a selective shift in mRNA isoform transcription. This VEGFR2 in conditioned
medium was full-length protein and was associated with increased soluble HSP-90, consistent with a possible
shedding of microvesicles/exosomes.
Conclusions: Taken together, our results suggest that endothelial cells exposed to TGF-β1 lose both tip and stalk
cell identity, possibly mediated by loss of VEGFR2 signaling. The role of these events in physiological and
pathological angiogenesis requires further investigation.
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Background
The cytokine transforming growth factor beta (TGF-β)
is a member of the TGF-β superfamily consisting of 33
members including TGF-βs (1–3) [1]. TGF-β1 is the
predominant and more ubiquitous form. TGF-β ligands
signal canonically through type I (ALK) and type II
serine/threonine kinase receptors [2], and via the
accessory (type III) receptor endoglin in vascular endo-
thelial cells [3]. TGF-β binding leads to phosphorylation
of intracellular R-Smads 1, 2, 3, 5 or 8 [2, 4], which then
complex with Co-Smad4, enter the nucleus and associate
with transcriptional co-activators or co-repressors to
regulate the expression of target genes.
TGF-β plays a dual role in angiogenesis by orchestrat-
ing a switch from vascular inhibition to pro-angiogenic
activity [5–7]. In particular, there is evidence that TGF-
β1 induced angiogenesis acts with VEGF to mediate
apoptosis of excessive vascular sprouts and may even be
required for initial sprouting from an existing vascular
network [8, 9]. The nature of the angiogenic response to
TGF-β depends on the balance of ALK1 versus ALK5
signaling input, with ALK1 predominantly promoting
sprouting and ALK5 favoring the resolution/stabilization
phase of angiogenesis [6]. Thus, TGF-β is either pro- or
anti-angiogenic, depending on which TGF-RII/Smad
pathway is engaged [10]. Differences also exist in the
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kinetics and dose responses of these pathways: ALK1
mediated signaling is transient and maximal at low con-
centrations of ligand while ALK5 mediated signaling is
sustained and maximal at higher doses of ligand [11].
Increased expression of endoglin led to inhibition of
TGF-β/ALK5 signaling (as demonstrated by Smad and
CAGA dependent reporter activity) in a dose dependent
fashion [12].
Activation of vascular sprouting during angiogenesis
entails the specification of endothelial cells into tip and
stalk cells. Endothelial tip cells are mainly migratory and
polarized with minimal proliferation while stalk cells
proliferate throughout sprout establishment and form
the nascent vascular lumen cells [13]. The delta-like lig-
and 4 (Dll4)-Notch1 signaling pathway is involved in
tip-stalk cell identity [14]. Tip cells express high levels of
Dll4 and vascular endothelial growth factor receptor-2
(VEGFR2), and have low levels of Notch signaling activ-
ity [13, 15, 16]. The specification of endothelial cells as
tip or stalk cells is transient and its reversibility is con-
tingent on the balance between pro-angiogenic factors.
Here we quantify the effect of TGF-β1 on in vitro
angiogenesis using a Matrigel cord formation assay, and
determine the impact of this angiogenic cytokine on ex-
pression of molecules associated with endothelial tip and
stalk cell identity.
Methods
Cells and culture conditions
Primary bovine aortic endothelial cells (BAEC) were
isolated and characterized as described [17] and used be-
tween passage 4 and 10. Cultures were maintained in
Dulbecco’s Modified Eagle Medium (DMEM; Sigma-
Aldrich) with 10% fetal bovine serum (FBS; Invitrogen)
and 1 mM sodium pyruvate (Sigma-Aldrich) at 37 °C in
5% CO2 and 95% atmospheric air. Confluent monolayers
were serum starved 16 h prior to treatment.
TGF-β1 dose-response
Serum starved BAEC were treated with 0 (Control), 0.1,
1.0, 5.0, or 10.0 ng/ml of recombinant human (rh) TGF-
β1 (R&D Systems) in serum free DMEM for up to 24 h,
± 5 μM SB-431542 (an inhibitor of TGβR-I isoforms
ALK-5, −4 and −7 [18]). Cell supernatant (conditioned
medium) was collected and centrifuged at 350 × g for
4 min, and adherent cells lysed for protein or RNA ana-
lysis. For some assays, conditioned medium was sub-
jected to additional ultracentrifugation (100,000 × g for
1 h at 4 °C) prior to western blotting.
Protein isolation and western blotting
Cells were lysed on ice with cell lysis buffer (Cell
Signaling) supplemented with 1% phosphatase inhibitor
cocktail 2 (Sigma-Aldrich), 2 μg/ml aprotinin (Sigma-
Aldrich) and 1 mM PMSF (Sigma-Aldrich). Total pro-
tein was quantified using the Bio-Rad system and elec-
trophoresis was performed with 20–30 μg protein plus
β-mercaptoethanol; samples were heated prior to SDS-
PAGE electrophoresis. Proteins were transferred to
PVDF membrane, blocked in 5% skim milk or 5% BSA
for 1 h at room temperature, then incubated in primary
antibody overnight at 4 °C. The antibodies used were:
mouse monoclonal anti-Adam 10 (sc-48400; 1:200) and
goat polyclonal anti-Adam 17 (sc-6416; 1:200); both
Santa Cruz Biotechnology; rabbit monoclonal anti-
endoglin (#4335; 1:1000), anti-Notch1 (#4380; 1:1000),
anti-VEGFR2 (#9698; 1:1000), anti-pVEGFR2 Tyr 951
(#4991; 1:1000), rabbit polyclonal anti-HSP90 (α and β
isoforms; #4874; 1:1000) and anti-pSMAD2 (#3101;
1:500), mouse monoclonal anti-SMAD2 (#3103; 1:1000),
all from Cell Signaling; rabbit polyclonal anti-Dll4
(ab7280; 1:1000) and anti-MMP-14 (ab73879; 1:500),
rabbit monoclonal anti-VEGFR1 (ab32152; 1:10000), all
from abcam; anti-α Tubulin (T5168; 1:200000, Sigma-
Aldrich). Membranes were washed and incubated with a
secondary antibody (goat anti-mouse HRP or goat anti-
rabbit HRP; 1:10,000; both Sigma-Aldrich) for 30 min at
room temperature. Bands were visualized with Luminata
Classico or Luminata Forte Western HRP Substrate
(Millipore) and membranes imaged using a ChemiDoc
MP Imaging System (Bio- Rad). Protein loading was nor-
malized by stripping and re-probing for α-tubulin,
followed by densitometry analysis.
RNA isolation and gene expression analysis
Cells were lysed in Ribozol (AMRESCO, VWR Inter-
national, Mississauga, ON) and RNA isolated using
Aurum Total RNA columns (Bio-Rad, Mississauga, ON)
according to manufacturers’ protocols. RNA was reverse-
transcribed with 4 μL iScript (BioRad, Mississauga, ON)
before amplification using primers for target and house-
keeping genes (Table 1). Ssofast EvaGreen Supermix
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(BioRad) was used to determine primer efficiency and for
quantitative PCR. No-template controls and quantitative
PCR reactions were run in triplicate with an initial 2 min
denaturation at 95 °C, 40 cycles of 95 °C for 5 s, 60 °C for
5 s, followed by melt curve analysis of 65 °C to 95 °C in
0.5 °C increments on the CFX96 RealTime System (Bio-
Rad). Full length and soluble splice variant mRNA for
VEGFR2 were first normalized to both HPRT and
GAPDH housekeeping genes, and then results from TGF-
β1-treated samples were expressed as relative amounts
normalized to control (untreated) samples. Data were ana-
lyzed using CFX Manager (Bio-Rad).
Matrigel cord formation assay
The impact of TGF-β1 and inhibitors on in vitro angio-
genesis was determined by cord formation assay. 10 μl
of growth factor containing BD Matrigel Matrix (cat #
354234; BD Biosciences) was added to each well of cold
angiogenesis μ-slides (ibidi) and allowed to gel at 37 °C
for 30 min. 50 μl of BAEC cell suspension containing 1
× 104 cells in Media-200 made with complete supple-
ments (GIBCO) plus or minus TGF-β1 and inhibitors
were added to each well. Slides were incubated for 8 h at
37 °C, and one image/well was captured with phase con-
trast microscopy using a 4X objective. The generation of
cord networks was quantified using the tube formation
assay analysis service Wimtube (http://www.wimasis.-
com; ibidi); analyzed parameters were total cord length,
# of branching points, and # of loops. # of tip cells was
also determined by manual count of phase contrast im-
ages; tip cells were defined as free-ended cells/sprouts
with visible filopodia.
Statistical analysis
All statistical analysis and graphing were performed
using GraphPad Prism 6 software (GraphPad Software).
Means for at least three biological replicates were calcu-
lated and plotted with standard error bars. Data were
analyzed by using the nonparametric Kruskal-Wallis test
followed by Dunn’s post hoc test for multiple compari-
sons, as appropriate. Differences between means were
considered statistically significant when the p value was
less than 0.05. Assays were performed in triplicate unless
otherwise indicated.
Results
Exogenous TGF-β1 induced a dose-dependent decrease
in endothelial cord formation on Matrigel, with signifi-
cant reductions in cord length, cord branching, loop for-
mation and tip cell generation detectable with doses of
TGF-β1 ≥ 1.0 ng/ml (Fig. 1). Western blotting of whole
cell lysates from BAEC treated with exogenous TGF-β1
under serum free conditions confirmed our previous
findings [19] of significant downregulation of VEGFR2,
and no alteration in VEGFR1 expression (Fig. 2 a-c).
VEGFR2 was detected as a doublet, with one band
approximately 230 kDa (thought to represent the full-
length mature transmembrane form), and a smaller
(~180–200 kDa) putative ‘immature’ isoform [20]. Re-
duction in cell associated VEGFR2 protein was seen in
both mature and immature forms, and was sustained for
at least 24 h after removal of exogenous TGF-β1
(Additional file 1: Figure S1). There was also significant
reduction in the levels of Notch1 but no changes in its
ligand Dll4 (Fig. 2 a, d, f ). TGF-β1 induced a profound
upregulation of the type III receptor endoglin (Fig. 2 a,
e) and concomitant activation of SMAD2 signaling, as
revealed by enhanced levels of phosphorylated SMAD2
(pSMAD2) (Fig. 2 a, g). SMAD2 activation was maximal
at 5.0 ng/ml TGF-β1, thus subsequent assays were
performed with this concentration.
The mechanisms of the observed changes in angio-
genic signaling pathways were then investigated. As
demonstrated by treatment with the ALK5 signaling in-
hibitor SB-431542 (SB, 5 μM), blockade of ALK5 signal-
ing significantly eliminated the ability of 5.0 ng/ml TGF-
β1 to inhibit Matrigel angiogenesis (Fig. 3 a). SB inhibi-
tor alone had no significant effect compared to DMSO
vehicle (Control) in these assays. Exogenous TGF-β1 led
to a reduction in VEGFR2 phosphorylation (as revealed
by western blotting for pVEGFR2 at residue tyrosine
951) and expression levels, but addition of the SB inhibi-
tor rescued VEGFR2 signaling (Fig. 4 a). Similar results
were obtained using SD-208, another ALK5 signaling in-
hibitor (Additional file 2: Figure S2). TGF-β1 activation
of SMAD2 phosphorylation and endoglin upregulation
was also blocked by SB (Fig. 4). Notch1 levels showed a
trend towards significant differences with SB inhibitor
(p = 0.07), but expression of Dll4 was not altered (Fig. 4).
SMAD1/5 phosphorylation was also not altered in these
samples. Thus, ALK5 appeared to mediate the effects of
TGF-β1 on the observed altered angiogenesis signaling
pathways.
The basis of VEGFR2 downregulation was further in-
vestigated. Loss of VEGFR2 from whole cell lysates of
TGF-β1 treated BAEC was accompanied by concomitant
increasing levels of full-length protein in serum free con-
ditioned media (CM) collected from the same cells (Fig. 5
a). qPCR analysis showed that both full-length and the
soluble VEGFR2 (sVEGFR2) splice variant mRNAs were
expressed by these cells, with the full-length isoform be-
ing the predominant species, expressed approximately
16 fold higher than the sVEGFR2 message. Both iso-
forms of VEGFR2 message were significantly downregu-
lated in TGF-β1 treated cells compared to control.
However, the ratio of full-length to soluble VEGFR2
mRNA was not altered by 5.0 ng/ml TGF-β1 treatment
(Fig. 5 b), supporting the finding from Fig. 5a that a
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truncated soluble form of VEGFR2 protein is not re-
leased from these cells upon TGF- β1 exposure.
No change in MMP-14 (MT1-MMP) or ADAM17
protein levels were detected, and ADAM10 was weakly
upregulated in TGF-β1 treated cells, suggesting enzym-
atic shedding was not the mechanism for increased CM-
associated VEGFR2 (Fig. 5 d). In contrast, increased
levels of the extracellular vesicle/exosome-associated
protein HSP90 were also detected in serum-free condi-
tioned medium from TGF-β1 treated cells (Fig. 5 d).
These data suggest that in addition to transcriptional
downregulation, full-length VEGFR2 is released from
TGF-β1 treated endothelial cells as a mechanism to
regulate angiogenesis.
Fig. 1 TGF-β1 induced dose-dependent reduction in endothelial cord formation. a Representative phase contrast images showing endothelial
cell cord formation 8 h after plating on Matrigel™ in the presence of exogenous TGF-β1 (0–10 ng/ml). Note higher magnification control panel
(0 ng/ml TGF-β1), showing tip cells (arrows) and loop of endothelial cords (asterisk). WimTube automated quantification of cord formation showed
that TGF-β1 significantly inhibits total cord length (b), cord branching (c), formation of loops (d), and generation of tip cells (e). TGF-β1 doses of
1.0 ng/ml or higher significantly inhibited cord formation compared to control (0 ng/ml) or 0.1 ng/ml. **p≤ 0.01; **p≤ 0.001; N = 4; Kruskal-Wallis
test. Scale bars = 300 μm
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Discussion
TGF-β1 induced a dose dependent inhibition of endo-
thelial cord formation and modulation of endothelial an-
giogenic receptor expression in an ALK5 dependent
fashion. We observed enhanced endoglin expression,
and reduced Notch1 and VEGFR2 expression, which
collectively abrogated tip cell formation and stalk elong-
ation. During sprouting angiogenesis, combined in-
creased VEGFR2 and reduced Notch1 signaling lead to
gain tip cell phenotype, and increased Notch1 signaling
promotes loss of tip cell phenotype [21, 22]. Our results
suggest that TGF-β1 interferes with tip/stalk cell identity
when ALK5/Smad2 signaling pathways are activated.
TGF-β-mediated ALK1 signaling serves to enhance
sprouting angiogenesis in part by indirectly inhibiting
TGF-β/ALK5 signaling [6]. Endoglin modulates the bal-
ance between ALK1 and ALK5 signaling, favouring a
pro-angiogenic phenotype [23]. However, in our study,
endoglin expression was highest in cells treated with
‘anti-angiogenic’ levels of TGF-β1 (5 ng/ml and higher),
which were also associated with ALK5/Smad2 activation.
Interestingly, activated (phosphorylated) Smad1/5 was
readily detected independent of TGF-β1 treatment.
Thus, in our system, tip cell identity may be the default
phenotype, which is repressed upon activation of ALK5/
Smad2 signaling, possibly via loss of Notch 1 and
VEGFR2 expression.
We saw concomitant loss of cell-associated full-length
VEGFR2 and increased levels of CM-associated full-
length VEGFR2 upon TGF-β1 exposure. Endothelial cells
are known to produce an alternatively spliced VEGFR2
mRNA, leading to transcripts lacking the transmem-
brane domain coded for by exon 13 [24, 25]. This
transcript codes for a soluble form of the receptor
(sVEGFR2), which could potentially account for the
presence of CM-associated VEGFR2 in our samples.
However, while both full length and alternatively spliced
VEGFR2 transcripts were detectable in BAEC, the full
Fig. 2 TGF- β1 induced dose-dependent changes in endothelial cell receptors. a Representative western blots of endothelial cells exposed to
exogenous TGF-β1 (0.1–10.0 ng/ml) for 24 h. Densitometry showed significantly reduced VEGFR2 expression (b), but no change in VEGFR1 (c) in
cells treated with higher doses of TGF-β1. The TGF-β1 co-receptor endoglin was significantly upregulated in a dose dependent fashion (e). Notch1
was significantly downregulated in endothelial cells treated with 5.0 and 10.0 ng/ml TGF-β1 (d), and its ligand Dll4 showed a trend towards re-
duced expression with higher doses (f). TGF-β1 signaling through ALK5/SMAD2-dependent pathways, as revealed by phosphorylation of SMAD2,
was maximal at doses of 5.0 ng/ml and higher (g). *p≤ 0.05; **p≤ 0.01; N = 3; Kruskal-Wallis test
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length VEGFR2 mRNA was by far the predominant iso-
form, and we found no evidence for a preferential shift
in production of message for sVEGFR2 in TGF-β1
treated cells. Further, the CM-associated VEGFR2 was
full-length protein as assessed by estimated molecular
mass. Thus, the source of VEGFR2 found in conditioned
medium is unlikely to be due to preferential translation
of a sVEGFR2 variant mRNA upon exposure to TGF-β1.
Alternatively, VEGFR2 could be cleaved from the
BAEC cell surface through proteolytic activity. The
matrix metalloproteinase MMP-14 (membrane type
MMP; MT1-MMP) is known to cleave the TGF-β type
Fig. 3 TGF-β1 induced reduction in endothelial cord formation occurs via an ALK5 related pathway. a Representative phase contrast images
showing endothelial cell cord formation 8 h after plating on Matrigel™ under control conditions (C; DMSO vehicle), 5 μM SB-431542 (an ALK5 in-
hibitor) in DMSO (SB), 5 ng/ml exogenous TGF-β1 (T) or 5.0 ng/ml TGF-β1 plus 5 μM SB-431542 (T + SB). b WimTube automated quantification of
cord formation showed SB inhibitor significantly blocked the ability of 5.0 ng/ml TGF-β1 to significantly inhibit total cord length, cord branching,
formation of loops, and generation of tip cells. SB inhibitor, either alone or in combination with 5.0 ng/ml TGF-β1 was not significantly different
from DMSO control. **p ≤ 0.01; ***p≤ 0.001; N = 4; Kruskal-Wallis test
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III receptor endoglin from endothelial cells, generating a
soluble form [26]. In our study, levels of MMP-14 were
weakly detectable by western blotting, and qPCR re-
vealed Cq values > 35 (data not shown). This, combined
with the lack of detectable soluble endoglin in BAEC
conditioned medium, suggests that MMP-14 cleavage of
surface protein is not a significant determinant of CM-
associated VEGFR2 in our system. A disintegrin and
metalloprotease (ADAM) family of enzymes act as ‘shed-
dases’, cleaving surface bound proteins to general soluble
isoforms. ADAM-17 is known to shed VEGFR2 from
endothelial [27] and non-endothelial [28] cell surfaces,
and VEGFR2 is a target of ADAM-10 mediated cleavage
in endothelial cells [29]. Both ADAM-10 and ADAM-17
were produced by BAECs, and there was weak induction
of ADAM-10 by TGF-β1 in our cells. However, such
sheddase activity would generate CM-associated
VEGFR2 molecules of ~130 kDa [27], but we only de-
tected full length (~250 kDa) VEGFR2 in conditioned
medium, consistent with an alternative mechanism for
Fig. 4 TGF-β1 induced reduction in receptor expression occurs via an ALK5 related pathway. a) Representative western blots and densitometry
(b) from BAEC exposed to control conditions (C; DMSO vehicle), 5 μM SB-431542 (an ALK5 inhibitor) in DMSO (SB), 5 ng/ml exogenous TGF-β1 (T)
or 5.0 ng/ml TGF-β1 plus 5 μM SB-431542 (T + SB) for 24 h. TGF-β1 leads reduced VEGFR2 expression and activation, and significantly upregulated
endoglin in an ALK5/SMAD2-dependent fashion (as revealed by pSMAD2). There were no significant changes in SMAD1/5-dependent signaling,
or in VEGFR1, Notch1 or Dll4 expression. *p≤ 0.05; N = 3; Kruskal-Wallis test
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release of this receptor from endothelial cells. Recent re-
ports suggest that prolonged surface residence of
VEGFR2 in HUVECs leads to protease-mediated cleav-
age and the generation of a soluble fragment of
~100 kDa and a residual cell associated 130 kDa frag-
ment [30]. As well, enhanced ubiquitination of VEGFR2
upon internalization in HUVECs leads to endosome-
lysosome pathway mediated fragmentation into 160 and
120 kDa fragments [31, 32]. The absence of such
VEGFR2 fragments in our samples suggests that TGF-β1
is not modulating VEGFR2 levels via these mechanisms
in these BAECs.
There is growing evidence that VEGFR2 signals cells
in an ‘autocrine’ or ‘intracrine’ fashion, leading to in-
creased receptor activity within the cytosolic (endosome)
and/or nuclear compartments [33–36]. Endothelial cells
can also release exosomes containing sequestered mole-
cules that then modulate neighbouring cells [37–39].
Endothelial cells expressing high levels of endoglin also
upregulate autophagy [40]. Autophagy may enhance
extracellular vesicle/exosome release via the mutivesicu-
lar body pathway, especially in serum starved endothelial
cells [41, 42]. These pathways may also be relevant for
tip/stalk cell specification during sprouting angiogenesis,
as tips cells display enhanced VEGFR2 turnover via
endocytosis and transfer from early endosomes to multi-
vesicular bodies [42, 43]. Further, Dll4 containing exo-
somes can be shed from endothelial cells, and Dll4
containing exosomes modulate tip cell phenotype during
sprouting angiogenesis [39, 44].
Fig. 5 TGF-β1 reduces VEGFR2 expression via multiple mechanisms. a Western blot showing TGF-β1 induced loss of cell associated VEGFR2
protein and concomitant increase in full-length VEGFR2 detected in conditioned medium. b Quantitative PCR analysis showed that there was no
change in the relative ratio of full length VEGFR2 mRNA to alternative spliced sVEGFR2 mRNA upon TGF-β1 treatment. c TGF-β1 treatment in-
duced increased expression of ADAM family sheddase enzyme ADAM 10. TGF-β1 treatment had no effect on the expression of ADAM 17 or the
membrane-associated metalloproteinase MMP-14. d Ultracentrifugation of endothelial conditioned medium demonstrated that soluble VEGFR2 is
associated with the extracellular vesicle/exosome marker HSP90 in TGF-β1 treated cells
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In agreement with the aforementioned findings, our re-
sults extend this activity to include the possibility that
shedding of VEGFR2 containing extracellular vesicles
(possibly exosomes) by vascular endothelium may be en-
hanced upon exposure to TGF-β1. We detected full length
VEGFR2 in serum free conditioned medium along with
the exosome marker HSP90. Retinal pigment epithelial
cells also shed exosomes containing VEGFR2 which sub-
sequently modulate endothelial cord formation in vitro
[45], but to our knowledge this is the first report that
VEGFR2 might be shed from endothelial cells themselves.
Conclusions
Here we report that TGF-β1 alters levels of key angio-
genic receptors, and interferes with tip/stalk cell identity
when ALK5/Smad2 signaling pathways are activated.
Our results suggest that downregulation of surface
VEGFR2 and concomitant increase in VEGFR2 levels in
endothelial cell conditioned medium may be a direct re-
sponse to ALK5-mediated TGF-β signaling. Exosome
shedding of VEGFR2 may rapidly limit the effects of an-
giogenic stimuli on the cells and stop further sprout for-
mation, but the role of these events in physiological and
pathological angiogenesis requires further investigation.
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Additional file 1: Figure S1. Time course of restoration of VEGFR2
expression. A) Western blot of BAEC treated with serum free media
containing 5 ng/ml TGF-β1 for 24 h, followed by recovery in serum free
medium lacking TGF-β1. Samples were collected after 0, 24, 48 and 72 h
recovery. Control culture (C) was treated with serum free medium lacking
TGF-β1 for 24 h. B) Densitometry of western blots showing significant re-
covery of VEGFR2 expression by 48 h post TGF-β1 treatment. * p < 0.001;
N = 2. (PDF 167 kb)
Additional file 2: Figure S2. ALK5 inhibitor SD-208 prevents TGF-β1
induced downregulation of VEGFR2 expression. Western blots showing
impact of increases doses of SD-208 on BAEC treated with DMSO vehicle
(0) or 5 ng/ml TGF-β1 for 24 h. (PDF 176 kb)
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